Research programme: drug discovery - Merck
Alternative Names: Drug discovery research programme - Merck & Co; PS 778629Latest Information Update: 29 Aug 2011
At a glance
- Originator Pharmacopeia Drug Discovery
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders; Inflammation; Metabolic disorders
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for CNS disorders in USA (PO)
- 29 Aug 2011 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 29 Aug 2011 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)